Literature DB >> 3668856

Contractile serotonergic receptor in rat stomach fundus.

M L Cohen1, L A Fludzinski.   

Abstract

Serotonin (5HT) is a potent agonist in contracting the rat stomach fundus although the nature of the receptor mediating the response has not been established. The present study was designed to explore the possibility that 5HT-induced contractions in the rat stomach fundus were mediated by interaction with receptors identical with either 5HT1A, 5HT1B or 5HT1C binding sites or 5HT3 receptors. Contractile concentration-response curves for several 5HT agonists [5-carboxamidotryptamine, TR3369, MK212, quipazine, RU 24969, 8-hydroxy-2-(di-n-propylamino)tetralin, TVXQ7821 and BEA 1654CL] were obtained in the rat stomach fundus. However, neither the potency nor maximum response of these agonists in contracting the rat stomach fundus correlated with the affinity of agonists at 5HT1A, 5Ht1B or 5HT1C binding sites. These agonists were interacting with 5HT receptors in the fundus based on the ability of 1-(1-naphthyl) piperazine (10(-7) M) to antagonize the contractile response of the relatively potent agonists. TVXQ7821 and BEA 1654Cl did not produce a marked contractile response in the fundus and also did not antagonize the contractile response to 5HT, suggesting that these agents have little, if any, affinity for the serotonergic receptor-mediating contraction in the fundus. The putative 5HT1A-selective receptor antagonists, WB4101 and spiroxatrine, did not block 5HT-induced contractions in the rat stomach fundus in concentrations consistent with their affinity at 5HT1A binding sites. The nonselective 5HT1A and 5HT1B receptor antagonist, cyanopindolol, also did not block 5HT-induced contractions in the rat stomach fundus.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3668856

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Analysis of the 5-HT receptor in rabbit saphenous vein exemplifies the problems of using exclusion criteria for receptor classification.

Authors:  G R Martin; S J MacLennan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-08       Impact factor: 3.000

2.  5-HT2B receptor-mediated calcium release from ryanodine-sensitive intracellular stores in human pulmonary artery endothelial cells.

Authors:  C Ullmer; H G Boddeke; K Schmuck; H Lübbert
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

3.  Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.

Authors:  G S Baxter; O E Murphy; T P Blackburn
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

4.  Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome.

Authors:  Nicholas L Meyers; Roger I Hickling
Journal:  Drugs R D       Date:  2008

Review 5.  Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift.

Authors:  Leif Hertz; Douglas L Rothman; Baoman Li; Liang Peng
Journal:  Front Behav Neurosci       Date:  2015-02-20       Impact factor: 3.558

6.  Pharmacological properties and discriminative stimulus effects of a novel and selective 5-HT2 receptor agonist AL-38022A [(S)-2-(8,9-dihydro-7H-pyrano[2,3-g]indazol-1-yl)-1-methylethylamine].

Authors:  Jesse A May; Najam A Sharif; Hwang-Hsing Chen; John C Liao; Curtis R Kelly; Richard A Glennon; Richard Young; Jun-Xu Li; Kenner C Rice; Charles P France
Journal:  Pharmacol Biochem Behav       Date:  2008-07-30       Impact factor: 3.697

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.